Animal Model Market - Growth, Trends, COVID-19, and Forecasts (2023-2028)

The animal model market is expected to register a CAGR of 8.6% over the forecast period.

The COVID-19 pandemic posed several challenges for the animal model market. For instance, an article published by NCBI, in July 2022, reported that, since the COVID-19 outbreak, animal models played a crucial role in aiding the rapid development of vaccines/drugs for the prevention and treatment of COVID-19, as well as understanding the pathogenesis of SARS-CoV-2 infection and immune responses of hosts, which led to increasing demand for animal models. However, due to the emergence of new SARS-CoV-2 strains and other new diseases, along with the continuous development of new drug molecules, the demand for animal models may continue to increase over the forecast period.

The rising usage of animal models in virology and infectious diseases, increased adoption of CRISPR technology, and an increasing number of R&D activities are driving the market's growth. The increasing number of infectious diseases leading to the death of billions of people worldwide have accelerated the development of vaccines, further increasing the use of animal models for drug testing studies. For instance, in February 2022, the WHO reported that 47,689 preclinical trial studies were registered in 2021. Thus, the increasing number of preclinical studies is also boosting the demand for animal models to conduct research, thereby driving the growth of the market.

The CRISPR-Cas system is used for target identification and validation, faster generation of safety models, and the development of cell-based therapies such as CAR-T cells for immunotherapy and CCR5 knockout cells for HIV treatment. Thus, the demand for animal models for production and quality control is increasing, thereby driving the market. For instance, an article published in the Molecular Neurobiology journal, in February 2022, reported that CRISPR/Cas9-based genome editing is becoming one of the most promising tools for treating human genetic diseases, including cardiovascular diseases, neuro-disorders, cancers, leading to the rising demand for animal genetic models for studying and treating human genetic disorders, particularly diseases associated with point mutations.

The development of CRISPR/Cas-9 technology is fueling the growth of the market. For instance, in September 2021, researchers from the Washington University School of Medicine used a mouse model to study the behavior of CRISPR-engineered cells for the treatment of rheumatoid arthritis. Hence, the increasing R&D in animal studies may further boost the growth of animal model market in the future.

However, regulations for the ethical use of animals may slow down the growth of the market over the forecast period.

Key Market Trends

Mice Segment is Expected to Exhibit Significant Growth During the Forecast Period

The mice model segment is expected to show significant growth in the market, primarily due to the increasing R&D activities in the pharmaceutical industries. For instance, in May 2022, the National Center for Health Statistics (NCHS) reported that the R&D expenses for various diseases, like brain cancer, were USD 415 million. It also reported that the R&D expenditure for brain disorders, cardiovascular disease, and coronavirus was USD 7,963 million, USD 2,544 million, and USD 1,922 million, respectively, in 2021. Thus, the rise in R&D expenses is leading to the increasing use of animal models for preclinical trial studies, thereby driving the growth of this segment.

Similarly, in September 2021, researchers from Sementis Ltd and the University of South Australia collaborated on COVID-19 vaccine development. The team employed mouse models to develop a vaccine that encodes SARS-CoV-2 spike glycoprotein. The successful use of mouse models to validate drug targets and determine efficacious and safe dosage schemes for combination treatments in humans is driving the growth of this segment.

Mice and humans have around 95% of similarity in DNA, and therefore, this model has a wide range of applications in various studies such as oncology, immunology and inflammation, central nervous system (anxiety and other disorders), cardiovascular, and diabetes. The emergence of COVID-19 prompted the use of mouse models to study its pathology and develop an effective treatment. Apart from COVID-19 studies, mice models are considered to be the best small animal models for hepatitis B virus (HBV), hepatitis C virus (HCV), Zika virus, and cytomegalovirus (CMV), among others.

The launch of new mice models is also fueling the growth of this segment. For instance, in December 2021, Inotiv Inc. launched novel transgenic rodent models designed specifically for SARS-CoV-2 and COVID-19 research. The mouse and rat models overcome the limitations of other commercially available human ACE2 transgenic rodent models, thus fuelling the segment's growth.

North America is Expected to Witness a Significant Growth During the Forecast Period

North America is expected to witness significant growth over the forecast period due to increasing investments and the number of clinical trials. The region is marked by the presence of major players operating in the mice model market, growing biomedical research in the United States, and rising preclinical activities by clinical research organizations (CROs) and pharmaceutical companies in the region.

The development of technologies such as CRISPR-cas is fueling the growth of the animal model market in the region. For instance, in October 2022, ChristianaCare, with hospitals and health facilities in Delaware, Maryland, Pennsylvania, and New Jersey, reported that it has established CorriXR Therapeutics, a biotechnology company that will leverage CRISPR gene editing technology to develop oncology therapeutics, with an initial focus on squamous cell carcinoma of the lung. Thus, such technological developments in the region increase the demand for an animal model, thereby driving the growth of the market.

Increasing expenditures on R&D activities in the pharmaceutical and biotechnology sector are likely to fuel the market's growth in the region. For instance, in June 2022, Statistics Canada reported that pharmaceutical and medicine manufacturing in Canada was anticipated to witness significant growth in 2021 and 2022 due to the increased funding. As a result, the market is expected to witness significant growth in the region. Similarly, an article published in Scientific Reports, in January 2021, reported that rat and mouse models comprise 99.3% of the mammals used in 16 large American institutions. Therefore, a high utilization rate of these models in the region propels revenue growth, thereby driving the growth of the market.

Competitive Landscape

The animal model market is fragmented and competitive and consists of a few major players. Some of the prominent players operating in the animal model market are Biocytogen Pharmaceuticals Co. Ltd, Charles River Laboratories International Inc., Labcorp UK Limited (Envigo Rms Inc.), Genoway, Harbour BioMed Co. Ltd, Hera Testing Laboratories Inc., Janvier Labs, Taconic Biosciences Inc., the Jackson Laboratory, Trans Genic Inc., JSR Corporation, Ozgene Holdings Pty Ltd, and PerkinElmer Inc. (Horizon Discovery Group PLC).

Additional benefits of purchasing the report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.